CFM
VIR icon

Catalyst Funds Management’s Vir Biotechnology VIR Stock Holding History

Catalyst Funds Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,300
Closed -$29.4K – 1619
2024
Q2 		$29.4K Sell
3,300
-2,600
-44% -$24.9K 0.01% 565
2024
Q1 		$59.8K Buy
+5,900
New +$60.1K 0.02% 516

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Catalyst Funds Management's VIR Position: Q3 2024 in Review

Catalyst Funds Management sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 3,300 shares — an estimated $29.4K sold.

Catalyst Funds Management first reported a position in VIR in Q1 2024 and held it in 2 quarters. The position peaked at $59.8K in Q1 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Catalyst Funds Management reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 3,300 Vir Biotechnology shares in Q3 2024, an estimated $29.4K.
  • Catalyst Funds Management first reported a position in Vir Biotechnology in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Vir Biotechnology position peaked at $59.8K in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.